This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 1616 |
novel coronavirus | 1427 |
acute respiratory | 1239 |
syndrome coronavirus | 1026 |
severe acute | 1000 |
coronavirus disease | 820 |
middle east | 686 |
east respiratory | 659 |
en el | 371 |
sars coronavirus | 370 |
coronavirus infection | 363 |
spike protein | 350 |
pacientes con | 299 |
public health | 278 |
human coronavirus | 261 |
severe covid | 260 |
united states | 255 |
en pacientes | 241 |
immune response | 234 |
confirmed cases | 229 |
clinical characteristics | 225 |
los pacientes | 223 |
se recomienda | 222 |
clinical trials | 208 |
viral rna | 203 |
respiratory distress | 198 |
cov infection | 197 |
critically ill | 196 |
respiratory tract | 190 |
con covid | 186 |
distress syndrome | 180 |
new coronavirus | 172 |
systematic review | 169 |
coronavirus pneumonia | 168 |
converting enzyme | 163 |
world health | 160 |
convalescent plasma | 158 |
intensive care | 154 |
health organization | 151 |
clinical trial | 149 |
hospitalized patients | 147 |
viral replication | 147 |
saudi arabia | 146 |
host cell | 145 |
en los | 144 |
immune system | 143 |
coronavirus infections | 142 |
doc id | 140 |
cord uid | 140 |
infected patients | 139 |
viral load | 137 |
clinical features | 137 |
infectious diseases | 136 |
coronavirus pandemic | 135 |
immune responses | 135 |
chest ct | 134 |
coronavirus spike | 134 |
cytokine storm | 134 |
type i | 133 |
pregnant women | 131 |
risk factors | 130 |
human coronaviruses | 130 |
respiratory disease | 130 |
bovine coronavirus | 130 |
lopinavir ritonavir | 129 |
el uso | 128 |
patients infected | 128 |
social distancing | 125 |
ill patients | 124 |
health care | 120 |
human transmission | 119 |
spike glycoprotein | 117 |
del paciente | 116 |
epithelial cells | 115 |
nucleocapsid protein | 113 |
incubation period | 113 |
neutralizing antibodies | 112 |
cohort study | 109 |
host cells | 109 |
rna viruses | 109 |
structural proteins | 108 |
hong kong | 108 |
sars cov | 107 |
sars virus | 106 |
viral infections | 106 |
rna polymerase | 105 |
receptor binding | 103 |
innate immune | 101 |
para el | 101 |
like protease | 100 |
ace receptor | 100 |
viral infection | 98 |
respiratory failure | 97 |
el paciente | 97 |
lung injury | 96 |
dromedary camels | 96 |
coronavirus hku | 96 |
por covid | 95 |
binding domain | 95 |
virus infection | 95 |
con el | 93 |
rna synthesis | 92 |
may also | 91 |
amino acid | 90 |
coronavirus outbreak | 89 |
infectious bronchitis | 89 |
south korea | 89 |
nucleic acid | 88 |
corona virus | 88 |
viral entry | 87 |
hepatitis virus | 86 |
disease control | 86 |
antiviral activity | 85 |
mortality rate | 84 |
disease severity | 84 |
infected pneumonia | 84 |
upper respiratory | 83 |
coronavirus replication | 82 |
care unit | 81 |
cell entry | 81 |
infectious peritonitis | 81 |
monoclonal antibodies | 81 |
feline infectious | 80 |
mechanical ventilation | 80 |
ebola virus | 80 |
first case | 79 |
animal models | 79 |
influenza virus | 78 |
new york | 77 |
sin embargo | 77 |
bat origin | 76 |
mouse hepatitis | 76 |
new cases | 76 |
fatality rate | 76 |
con sospecha | 76 |
confirmed covid | 75 |
clinical course | 75 |
coronavirus crisis | 74 |
associated coronavirus | 74 |
severe cases | 74 |
severe disease | 73 |
protective equipment | 73 |
sars patients | 72 |
infectious disease | 72 |
infected cells | 72 |
vaccine development | 72 |
bronchitis virus | 71 |
case series | 71 |
con un | 71 |
paciente con | 71 |
randomized clinical | 69 |
global health | 69 |
antibody responses | 69 |
mers coronavirus | 69 |
genome sequence | 68 |
enteric coronavirus | 67 |
accessory proteins | 66 |
personal protective | 65 |
neutralizing antibody | 65 |
con una | 65 |
disgust proneness | 64 |
coronavirus associated | 63 |
virus replication | 63 |
en un | 63 |
se ha | 62 |
person transmission | 62 |
antiviral drugs | 62 |
cell responses | 62 |
virus disease | 62 |
case fatality | 62 |
por el | 61 |
descriptive study | 61 |
viral shedding | 61 |
monoclonal antibody | 60 |
rights reserved | 60 |
situation report | 60 |
lower respiratory | 60 |
spectrum antiviral | 60 |
replicative structures | 59 |
closely related | 59 |
contact tracing | 58 |
hubei province | 58 |
controlled trial | 58 |
viral genome | 58 |
immune cells | 57 |
membrane fusion | 57 |
dependent rna | 57 |
por sars | 56 |
transmissible gastroenteritis | 56 |
human respiratory | 56 |
el manejo | 56 |
genome sequences | 56 |
recent study | 55 |
inflammatory cytokines | 55 |
nervous system | 54 |
se debe | 54 |
also reported | 54 |
chain reaction | 53 |
severe pneumonia | 53 |
climate change | 53 |
ncov infection | 53 |
virus entry | 53 |
increased risk | 53 |
tested positive | 53 |
amino acids | 53 |
pneumonia outbreak | 53 |
transmission dynamics | 53 |
observational study | 53 |
polymerase chain | 53 |
un estudio | 53 |
stranded rna | 53 |
clinical signs | 52 |
pacientes en | 52 |
el riesgo | 52 |
machine learning | 52 |
protease inhibitors | 51 |
viral proteins | 51 |
mental health | 51 |
en las | 50 |
endoplasmic reticulum | 50 |
case report | 50 |
related coronavirus | 50 |
vertical transmission | 50 |
gene expression | 50 |
icu patients | 49 |
united kingdom | 49 |
porcine epidemic | 49 |
coronavirus sars | 49 |
seafood market | 49 |
animal species | 49 |
million people | 49 |
human ace | 48 |
respiratory infections | 48 |
health emergency | 48 |
family cluster | 48 |
severe respiratory | 48 |
dry cough | 48 |
se puede | 48 |
specific antibodies | 48 |
granted medrxiv | 48 |
feline coronavirus | 48 |
author funder | 48 |
clinical presentation | 47 |
peripheral blood | 47 |
infected individuals | 47 |
symptom onset | 47 |
total number | 47 |
reverse transcription | 47 |
retrospective cohort | 47 |
cov spike | 47 |
ct findings | 47 |
even though | 46 |
spike proteins | 46 |
clinical manifestations | 46 |
respiratory illness | 46 |
novel human | 46 |
dna vaccine | 46 |
cuidados intensivos | 45 |
rna genome | 45 |
coronavirus cases | 45 |
isothermal amplification | 45 |
rna virus | 45 |
por lo | 45 |
bat coronavirus | 45 |
phylogenetic analysis | 45 |
open reading | 45 |
protease inhibitor | 44 |
respiratory coronavirus | 44 |
respiratory viruses | 44 |
human monoclonal | 44 |
cell membrane | 44 |
functional receptor | 44 |
safety behaviors | 44 |
bat coronaviruses | 44 |
respiratory symptoms | 44 |
randomized controlled | 44 |
envelope protein | 44 |
coronavirus isolated | 44 |
antiviral drug | 43 |
another study | 43 |
el grupo | 43 |
coronavirus nucleocapsid | 43 |
i interferon | 43 |
heart failure | 43 |
cell culture | 43 |
disease map | 43 |
central nervous | 43 |
coronavirus vaccine | 42 |
acute lung | 42 |
el tratamiento | 42 |
inflammatory response | 42 |
like particles | 42 |
en una | 42 |
higher risk | 42 |
familial cluster | 42 |
septic shock | 41 |
dendritic cells | 41 |
therapeutic options | 41 |
plasma therapy | 41 |
complete genome | 41 |
chinese medicine | 41 |
risk factor | 41 |
clinical studies | 41 |
viral loads | 41 |
critical care | 40 |
electron microscopy | 40 |
intermediate host | 40 |
important role | 40 |
reproduction number | 40 |
murine coronavirus | 40 |
copyright holder | 40 |
traditional chinese | 40 |
adaptive immune | 40 |
intermediate hosts | 40 |
avian influenza | 40 |
evolutionary psychology | 40 |
close contact | 40 |
receptor recognition | 40 |
control measures | 40 |
en cuenta | 39 |
cell surface | 39 |
potential therapeutic | 39 |
respiratory droplets | 39 |
emerging coronaviruses | 39 |
healthcare workers | 39 |
sialic acid | 39 |
outbreak associated | 39 |
cov replication | 39 |
probable bat | 39 |
plasma convaleciente | 39 |
highly pathogenic | 39 |
epidemic diarrhea | 39 |
early stages | 38 |
economic growth | 38 |
factors associated | 38 |
main protease | 38 |
air pollution | 38 |
including sars | 38 |
dipeptidyl peptidase | 38 |
care workers | 38 |
clinical outcomes | 37 |
nonstructural protein | 37 |
infect humans | 37 |
cleavage site | 37 |
viral pneumonia | 37 |
face masks | 37 |
different countries | 37 |
clinical symptoms | 37 |
artificial intelligence | 37 |
vaccine candidate | 37 |
virus origins | 37 |
deep learning | 37 |
also found | 37 |
coronavirus indicating | 37 |
computed tomography | 37 |
retrospective study | 37 |
oxidative stress | 36 |
wide range | 36 |
cancer patients | 36 |
porcine deltacoronavirus | 36 |
extra shopping | 36 |
nonstructural proteins | 36 |
wild animals | 36 |
bat sars | 36 |
southern china | 36 |
se han | 36 |
authors declare | 36 |
cardiovascular disease | 36 |
sequence analysis | 36 |
humanistic psychology | 36 |
interim guidance | 36 |
treat covid | 36 |
pao fio | 36 |
life cycle | 35 |
multiple organ | 35 |
proinflammatory cytokines | 35 |
human covs | 35 |
antibody response | 35 |
early stage | 35 |
dependent enhancement | 35 |
organ failure | 35 |
receptor ace | 35 |
crystal structure | 35 |
genomic characterization | 35 |
diabetes mellitus | 35 |
risk assessment | 35 |
infection control | 35 |
rhesus macaques | 35 |
respiratory syncytial | 35 |
human airway | 35 |
death toll | 35 |
study clinical | 35 |
feline enteric | 35 |
con los | 35 |
data set | 34 |
high risk | 34 |
new virus | 34 |
coronavirus rna | 34 |
cov infections | 34 |
large number | 34 |
membrane protein | 34 |
sore throat | 34 |
genomic rna | 34 |
common cold | 34 |
target cells | 34 |
nk cells | 34 |
protein structure | 34 |
dengue virus | 34 |
cl pro | 34 |
drug repurposing | 34 |
coronavirus genome | 34 |
one study | 34 |
serine protease | 33 |
clinical findings | 33 |
effectively inhibit | 33 |
made available | 33 |
prime minister | 33 |
chloroquine phosphate | 33 |
bronchoalveolar lavage | 33 |
pp ab | 33 |
sequence identity | 33 |
phase i | 33 |
side effects | 33 |
type ii | 33 |
coronavirus nl | 33 |
genomic characterisation | 33 |
pneumonia associated | 33 |
inflammatory responses | 33 |
virus infections | 33 |
wuhan city | 33 |
dans les | 33 |
innate immunity | 33 |
case reports | 33 |
population density | 32 |
previous studies | 32 |
syncytial virus | 32 |
epidemiological characteristics | 32 |
rapid detection | 32 |
medical supplies | 32 |
todos los | 32 |
cell lines | 32 |
respiratory infection | 32 |
early transmission | 32 |
strand rna | 32 |
mediated isothermal | 32 |
first time | 32 |
china clinical | 32 |
cell receptor | 32 |
case study | 32 |
recovered patients | 32 |
several studies | 32 |
en su | 32 |
genome sequencing | 32 |
vitro studies | 31 |
patients hospitalized | 31 |
molecular docking | 31 |
fip disease | 31 |
different types | 31 |
fip coronavirus | 31 |
pulmonary disease | 31 |
infection prevention | 31 |
emergency use | 31 |
su uso | 31 |
reactive protein | 31 |
social media | 31 |
respiratory diseases | 31 |
diarrhea virus | 31 |
nitric oxide | 31 |
molecular mechanisms | 31 |
coronavirus nsp | 31 |
clinical management | 31 |
terminal domain | 30 |
del virus | 30 |
avian coronaviruses | 30 |
within days | 30 |
national health | 30 |
zika virus | 30 |
ace expression | 30 |
sars epidemic | 30 |
stem cell | 30 |
los estudios | 30 |
coronavirus antibodies | 30 |
cytokine release | 30 |
novel sars | 30 |
recently emerged | 30 |
en uci | 30 |
pandemic disgust | 30 |
debe ser | 30 |
mouse model | 30 |
high levels | 30 |
close contacts | 29 |
infected people | 29 |
therapeutic agents | 29 |
high mortality | 29 |
es un | 29 |
global pandemic | 29 |
coronavirus receptor | 29 |
patients admitted | 29 |
replication complex | 29 |
nsp protein | 29 |
viral particles | 29 |
sars outbreak | 29 |
family coronaviridae | 29 |
como el | 29 |
angiotensin converting | 29 |
molecular biology | 29 |
gastroenteritis virus | 29 |
additional information | 29 |
host immune | 29 |
multiple sclerosis | 29 |
coronavirus nonstructural | 28 |
study group | 28 |
atypical pneumonia | 28 |
calf diarrhea | 28 |
vaccine candidates | 28 |
recent studies | 28 |
data analysis | 28 |
coronavirus anxiety | 28 |
covid patients | 28 |
widely used | 28 |
protective immunity | 28 |
immunodeficiency virus | 28 |
con sdra | 28 |
study also | 28 |
viral envelope | 28 |
treatment options | 28 |
travel restrictions | 28 |
version posted | 28 |
emerged novel | 28 |
like coronavirus | 28 |
may lead | 28 |
drug discovery | 28 |
el cual | 28 |
current knowledge | 27 |
cell epitopes | 27 |
clinical study | 27 |
chinese center | 27 |
one health | 27 |
winter dysentery | 27 |
pediatric patients | 27 |
human infection | 27 |
pcr testing | 27 |
indicating person | 27 |
east asia | 27 |
medical staff | 27 |
coronavirus envelope | 27 |
asymptomatic cases | 27 |
chloroquine effectively | 27 |
puede ser | 27 |
also known | 27 |
structural protein | 27 |
may occur | 27 |
clinical specimens | 27 |
communicable diseases | 27 |
ace receptors | 27 |
procedural justice | 27 |
patients treated | 26 |
peritonitis virus | 26 |
may play | 26 |
supportive care | 26 |
cell response | 26 |
phylogenetic tree | 26 |
analysis based | 26 |
adverse effects | 26 |
human cells | 26 |
international committee | 26 |
donald trump | 26 |
patients showed | 26 |
en contra | 26 |
en este | 26 |
ct imaging | 26 |
health commission | 26 |
cruise ship | 26 |
international license | 26 |
infected person | 26 |
basic reproduction | 26 |
reported cases | 26 |
species transmission | 26 |
genetic recombination | 26 |
rna replication | 26 |
therapeutic strategies | 26 |
pandemic influenza | 26 |
like coronaviruses | 26 |
human population | 26 |
el momento | 26 |
el inicio | 26 |
gene source | 26 |
i ifn | 26 |
interferon beta | 26 |
suspected covid | 25 |
sobre el | 25 |
significantly higher | 25 |
data collection | 25 |
patients may | 25 |
heptad repeat | 25 |
structural studies | 25 |
mers patients | 25 |
will help | 25 |
cov rna | 25 |
reading frames | 25 |
el tiempo | 25 |
current pandemic | 25 |
reading frame | 25 |
coronavirus epidemic | 25 |
reproductive number | 25 |
positive patients | 25 |
los cuales | 25 |
los casos | 25 |
structural basis | 25 |
severe illness | 25 |
gastrointestinal symptoms | 25 |
chest radiography | 25 |
urgent need | 25 |
es importante | 25 |
whole genome | 25 |
virus particles | 25 |
north america | 25 |
coronavirus papain | 25 |
cuidado intensivo | 25 |
coronavirus oc | 25 |
influenza viruses | 25 |
emerging viruses | 25 |
among patients | 25 |
entre los | 25 |
two weeks | 25 |
organ dysfunction | 25 |
host range | 25 |
viral clearance | 24 |
release syndrome | 24 |
antiviral effects | 24 |
tract infections | 24 |
teniendo en | 24 |
therapeutic efficacy | 24 |
time series | 24 |
poor prognosis | 24 |
canine coronavirus | 24 |
signaling pathway | 24 |
rapid spread | 24 |
palm civets | 24 |
many countries | 24 |
en china | 24 |
two different | 24 |
binding affinity | 24 |
antibody titers | 24 |
time rt | 24 |
healthcare professionals | 24 |
igg antibodies | 24 |
pulmonary embolism | 24 |
bat species | 24 |
lung cells | 24 |
pathogenic coronavirus | 24 |
may result | 24 |
patients requiring | 24 |
treating covid | 24 |
imaging features | 24 |
humoral response | 24 |
see prokoplab | 24 |
also detected | 24 |
horseshoe bats | 24 |
neurological manifestations | 24 |
human cases | 24 |
imaging findings | 24 |
mortality rates | 24 |
disseminated intravascular | 24 |
approved drugs | 24 |
causative agent | 24 |
intravascular coagulation | 24 |
el personal | 24 |
emerging infectious | 24 |
pl pro | 24 |
oral transmission | 24 |
early phase | 24 |
en caso | 24 |
hand hygiene | 23 |
local transmission | 23 |
effective treatment | 23 |
guangdong province | 23 |
es el | 23 |
reverse transcriptase | 23 |
pathological findings | 23 |
virus genome | 23 |
human beings | 23 |
respiratory system | 23 |
clinical improvement | 23 |
american college | 23 |
pathogenic coronaviruses | 23 |
pneumonia cases | 23 |
hospital admission | 23 |
health workers | 23 |
myocardial injury | 23 |
increasing number | 23 |
early diagnosis | 23 |
direct contact | 23 |
label non | 23 |
disease caused | 23 |
animal covs | 23 |
coronavirus covid | 23 |
si el | 23 |
lung pathology | 23 |
better understand | 23 |
species barrier | 23 |
adult patients | 22 |
adults hospitalized | 22 |
antiviral therapy | 22 |
respiratory samples | 22 |
based vaccine | 22 |
indoor air | 22 |
use authorization | 22 |
emerging viral | 22 |
avian infectious | 22 |
membrane vesicles | 22 |
para evitar | 22 |
cardiac injury | 22 |
health authorities | 22 |
class i | 22 |
health concern | 22 |
confirmed case | 22 |
porcine respiratory | 22 |
serological tests | 22 |
es una | 22 |
estos pacientes | 22 |
western medicine | 22 |
health system | 22 |
genome analysis | 22 |
consentimiento informado | 22 |
ill covid | 22 |
human immunodeficiency | 22 |
may contribute | 22 |
del estado | 22 |
airway epithelial | 22 |
lactate dehydrogenase | 22 |
preventive measures | 22 |
air quality | 21 |
myocardial infarction | 21 |
time reverse | 21 |
genomic sequence | 21 |
significantly lower | 21 |
available data | 21 |
nlrp inflammasome | 21 |
important lessons | 21 |
mesenchymal stem | 21 |
like virus | 21 |
clinically proven | 21 |
cual se | 21 |
healthcare settings | 21 |
may cause | 21 |
novel coronaviruses | 21 |
consensus statement | 21 |
humoral immune | 21 |
emerging novel | 21 |
progressive politics | 21 |
bovine enteric | 21 |
molecule inhibitors | 21 |
acute kidney | 21 |
asymptomatic patients | 21 |
coronavirus pathogenesis | 21 |
literature review | 21 |
candidate vaccines | 21 |
coronavirus case | 21 |
para los | 21 |
first cases | 21 |
cov outbreak | 21 |
standard care | 21 |
icu admission | 21 |
virus transmission | 21 |
pregnant patients | 21 |
encephalomyelitis virus | 21 |
affected countries | 21 |
antiviral treatment | 21 |
transplant recipients | 21 |
tourism research | 21 |
una serie | 21 |
like sars | 21 |
diamond princess | 21 |
long structural | 21 |
healthy control | 21 |
blood pressure | 21 |
positive selection | 21 |
han sido | 21 |
para pacientes | 21 |
study showed | 21 |
heart disease | 21 |
falla respiratoria | 21 |
severe coronavirus | 21 |
first reported | 21 |
stem cells | 21 |
kidney injury | 21 |
swine acute | 21 |
angiotensin ii | 20 |
may provide | 20 |
procedural fairness | 20 |
positive results | 20 |
systems biology | 20 |
domestic animals | 20 |
coronaviridae family | 20 |
clinical outcome | 20 |
inhibitors targeting | 20 |
hasta el | 20 |
immune evasion | 20 |
small molecule | 20 |
will also | 20 |
pathogen threat | 20 |
severe symptoms | 20 |
interferon response | 20 |
lo tanto | 20 |
nasopharyngeal swab | 20 |
test results | 20 |
arabian peninsula | 20 |
sense rna | 20 |
laboratory testing | 20 |
present study | 20 |
community transmission | 20 |
positive cases | 20 |
phase iii | 20 |
neurological complications | 20 |
mers cases | 20 |
mild symptoms | 20 |
observational studies | 20 |
across countries | 20 |
genetic diversity | 20 |
complement system | 20 |
random forest | 20 |
common symptoms | 20 |
tandem repeats | 20 |
infants born | 20 |
may help | 20 |
influenza pandemic | 20 |
viral diseases | 20 |
family members | 20 |
coronavirus entry | 20 |
tratamiento con | 20 |
like proteinase | 20 |
clinical status | 20 |
mg kg | 20 |
neonatal calf | 20 |
novel virus | 20 |
genome structure | 20 |
neutralising antibodies | 20 |
intravenous immunoglobulin | 20 |
adult inpatients | 20 |
creative commons | 19 |
coronavirus replicase | 19 |
virus rna | 19 |
inhibit sars | 19 |
royal college | 19 |
antiviral effect | 19 |
study reported | 19 |
currently available | 19 |
specific igg | 19 |
en cuanto | 19 |
mrna vaccine | 19 |
coronavirus shedding | 19 |
antiviral agents | 19 |
available online | 19 |
cell types | 19 |
newly identified | 19 |
risk management | 19 |
dna vaccines | 19 |
proven protease | 19 |
coronavirus symptoms | 19 |
travel history | 19 |
st century | 19 |
cell activation | 19 |
specific antibody | 19 |
crucial role | 19 |
scientific community | 19 |
previously described | 19 |
gastrointestinal tract | 19 |
surface stability | 19 |
disease outbreak | 19 |
infection may | 19 |
many people | 19 |
asymptomatic infections | 19 |
em structure | 19 |
contar con | 19 |
endothelial cells | 19 |
behavioral immune | 19 |
general population | 19 |
health measures | 19 |
nsp nsp | 19 |
control subjects | 19 |
protease tmprss | 19 |
highly contagious | 19 |
alto flujo | 19 |
pregnant woman | 19 |
like covs | 19 |
disease avoidance | 19 |
el estudio | 19 |
antiviral response | 19 |
gastroenteritis coronavirus | 19 |
lo cual | 19 |
inflammatory syndrome | 19 |
las recomendaciones | 19 |
entry depends | 19 |
viral nucleic | 19 |
emerging human | 19 |
cellular immune | 19 |
hemagglutinating encephalomyelitis | 19 |
visiting wuhan | 19 |
disease patients | 19 |
potent neutralization | 19 |
associated pneumonia | 19 |
suspected cases | 19 |
like receptors | 19 |
comparative analysis | 19 |
viral transmission | 19 |
cell membranes | 19 |
protein interactions | 19 |
en covid | 19 |
coronavirus family | 19 |
see table | 18 |
coronavirus antibody | 18 |
tratados con | 18 |
input sequence | 18 |
hospital mortality | 18 |
mild cases | 18 |
forma rutinaria | 18 |
aldosterone system | 18 |
police legitimacy | 18 |
transmission potential | 18 |
small intestine | 18 |
se sugiere | 18 |
adverse events | 18 |
desde el | 18 |
cases reported | 18 |
acuerdo con | 18 |
las cuales | 18 |
urban areas | 18 |
long time | 18 |
potential role | 18 |
swine enteric | 18 |
nk cell | 18 |
oxygen therapy | 18 |
study found | 18 |
mononuclear cells | 18 |
oropharyngeal swabs | 18 |
pulmonary edema | 18 |
coronavirus detection | 18 |
fusion inhibitors | 18 |
durante el | 18 |
community spread | 18 |
world bank | 18 |
virus assembly | 18 |
clinical progression | 18 |
high viral | 18 |
digestive system | 18 |
i clinical | 18 |
big data | 18 |
coronavirus strains | 18 |
kawasaki disease | 18 |
moderate covid | 18 |
mrna decay | 18 |
emerging coronavirus | 18 |
laboratory findings | 18 |
active site | 18 |
early containment | 18 |
observational cohort | 18 |
data suggest | 18 |
current covid | 18 |
novel corona | 18 |
randomized trials | 18 |
sample size | 18 |
pilot study | 18 |
prospective study | 18 |
syndrome clinical | 18 |
ncov pneumonia | 18 |
strict lockdown | 18 |
genome replication | 18 |
narrative review | 18 |
virus strain | 18 |
los efectos | 18 |
venous thromboembolism | 18 |
urgently needed | 18 |
coagulation parameters | 18 |
multisystem inflammatory | 18 |
protein kinase | 18 |
human sars | 18 |
coronavirus genomes | 18 |
genetic material | 18 |
ct scan | 18 |
countries like | 18 |
health professionals | 18 |
diagnostic methods | 18 |
transmembrane serine | 18 |
alveolar damage | 18 |
migrant workers | 18 |
necrosis factor | 18 |
york city | 18 |
recomienda en | 18 |
term compliance | 18 |
respiratory specimens | 18 |
cuando se | 18 |
developing countries | 18 |
con enfermedad | 18 |
whole world | 18 |
lavage fluid | 18 |
additional file | 17 |
publicly reported | 17 |
gas emissions | 17 |
china coronavirus | 17 |
severe sars | 17 |
coronavirus vaccines | 17 |
human cell | 17 |
en estado | 17 |
compassionate use | 17 |
will continue | 17 |
symptomatic patients | 17 |
tyrosine kinase | 17 |
drug administration | 17 |
asymptomatic contact | 17 |
oral route | 17 |
cytokine production | 17 |
potential vaccine | 17 |
mers coronaviruses | 17 |
fight covid | 17 |
future outbreaks | 17 |
one hand | 17 |
preliminary report | 17 |
viruses related | 17 |
new insights | 17 |
south korean | 17 |
del covid | 17 |
per day | 17 |
health crisis | 17 |
total deaths | 17 |
cov nsp | 17 |
protein nsp | 17 |
preliminary results | 17 |
virus spread | 17 |
exponential growth | 17 |
disease positive | 17 |
live attenuated | 17 |
reported confirmed | 17 |
lockdown measures | 17 |
transgenic mice | 17 |
modelling study | 17 |
citation networks | 17 |
high frequency | 17 |
medrxiv preprint | 17 |
coronavirus study | 17 |
equine coronavirus | 17 |
ncov infected | 17 |
las condiciones | 17 |
human lung | 17 |
lessons learned | 17 |
among others | 17 |
emergency department | 17 |
cell fusion | 17 |
cell line | 17 |
orf ab | 17 |
neural network | 17 |
nasal cannula | 17 |
severe patients | 17 |
host factors | 17 |
hospital stay | 17 |
will need | 17 |
european countries | 17 |
respiratory tracts | 17 |
invasive mechanical | 17 |
angiotensin system | 17 |
glass opacities | 17 |
recent insights | 17 |
also called | 17 |
plasma membrane | 17 |
respiratory virus | 17 |
antibody test | 17 |
care units | 17 |
four genera | 17 |
control strategies | 17 |
infected cases | 17 |
endothelial cell | 17 |
study conducted | 17 |
signaling pathways | 17 |
cell death | 17 |
una estrategia | 17 |
tissue tropism | 17 |
nucleotide identity | 17 |
early detection | 17 |
like viruses | 17 |
clinical microbiology | 17 |
novel cov | 17 |
critical illness | 17 |
ace protein | 17 |
replication cycle | 17 |
acid detection | 17 |
elevated levels | 16 |
viral spike | 16 |
animal coronaviruses | 16 |
bibliometric analysis | 16 |
mild disease | 16 |
oxygen saturation | 16 |
serum antibody | 16 |
receptor usage | 16 |
elderly patients | 16 |
disease progression | 16 |
bone marrow | 16 |
disease transmission | 16 |
future research | 16 |
manejo del | 16 |
infected patient | 16 |
clinically approved | 16 |
compromiso pulmonar | 16 |
lung damage | 16 |
differential diagnosis | 16 |
animal market | 16 |
serological assays | 16 |
lung disease | 16 |
also associated | 16 |
target cell | 16 |
surgical procedures | 16 |
flow nasal | 16 |
adenovirus type | 16 |
ha sido | 16 |
recent developments | 16 |
prospective cohort | 16 |
infection rate | 16 |
el sars | 16 |
pueden ser | 16 |
hemorrhagic fever | 16 |
protein interaction | 16 |
viral species | 16 |
potential treatment | 16 |
high scores | 16 |
comparado con | 16 |
causing severe | 16 |
based vaccines | 16 |
prefusion conformation | 16 |
patients without | 16 |
replicase proteins | 16 |
controlled trials | 16 |
infection among | 16 |
molecular epidemiology | 16 |
avian coronavirus | 16 |
host receptor | 16 |
immunosorbent assay | 16 |
cell cultures | 16 |
seir model | 16 |
recent years | 16 |
least one | 16 |
also shown | 16 |
host innate | 16 |
les coronavirus | 16 |
global public | 16 |
virus may | 16 |
recent advances | 16 |
northern italy | 16 |
dromedary camel | 16 |
receptor blockers | 16 |
surgical masks | 16 |
united arab | 16 |
noninvasive ventilation | 16 |
healthcare expenditures | 16 |
diarrhea coronavirus | 16 |
del tratamiento | 16 |
related coronaviruses | 16 |
coronavirus coronavirus | 16 |
mers cov | 16 |
genetic sequence | 16 |
broad spectrum | 16 |
bat cov | 16 |
clinical diagnosis | 16 |
arab emirates | 16 |
para su | 16 |
multicenter study | 16 |
mainland china | 16 |
binding site | 16 |
initial virological | 16 |
una vez | 16 |
health systems | 16 |
respiratory support | 16 |
transmission routes | 16 |
logistic regression | 16 |
tumor necrosis | 16 |
cause severe | 16 |
carga viral | 16 |
clinical practice | 16 |
cell rna | 16 |
like proteases | 16 |
supply chain | 16 |
nucleic acids | 16 |
general public | 16 |
global depression | 16 |
patients receiving | 16 |
pcr assay | 16 |
viral particle | 16 |
may develop | 16 |
cols en | 16 |
coronavirus infectious | 16 |
linked immunosorbent | 16 |
negative rt | 16 |
los servicios | 16 |
los trabajadores | 16 |
evidence suggests | 16 |
platelet count | 16 |
igm antibodies | 16 |
qt interval | 16 |
del uso | 16 |
healthy adults | 16 |
como una | 16 |
lateral flow | 16 |
like receptor | 16 |
supplementary material | 16 |
las personas | 15 |
table shows | 15 |
inflammatory cytokine | 15 |
tissue distribution | 15 |
precautionary measures | 15 |
consider cytokine | 15 |
asymptomatic carrier | 15 |
current status | 15 |
fatality rates | 15 |
virus strains | 15 |
cov genome | 15 |
genus betacoronavirus | 15 |
emitir una | 15 |
years old | 15 |
protein structures | 15 |
sense single | 15 |
clinical guidance | 15 |
pneumonia clinical | 15 |
comparative study | 15 |
high affinity | 15 |
york times | 15 |
dimer levels | 15 |
swine flu | 15 |
pandemia covid | 15 |
supplemental oxygen | 15 |
el estado | 15 |
imported case | 15 |
significant role | 15 |
community outbreak | 15 |
host receptors | 15 |
rheumatoid arthritis | 15 |
outside china | 15 |
imported cases | 15 |
phase trial | 15 |
significant difference | 15 |
huanan seafood | 15 |
diffuse alveolar | 15 |
las medidas | 15 |
treat sars | 15 |
natural host | 15 |
coronavirus orf | 15 |
cardiovascular system | 15 |
vaccine design | 15 |
zoonotic spillover | 15 |
health literacy | 15 |
dificultad respiratoria | 15 |
first days | 15 |
effective vaccine | 15 |
also identified | 15 |
may increase | 15 |
los niveles | 15 |
cellular receptors | 15 |
disease outbreaks | 15 |
si se | 15 |
five children | 15 |
biological properties | 15 |
pacientes covid | 15 |
los primeros | 15 |
informed consent | 15 |
chronic obstructive | 15 |
potent inhibitor | 15 |
recomienda realizar | 15 |
involving patients | 15 |
similar results | 15 |
specific human | 15 |
entre el | 15 |
better understanding | 15 |
control study | 15 |
risk handling | 15 |
diseases like | 15 |
con las | 15 |
randomized trial | 15 |
perceived stress | 15 |
genetic analysis | 15 |
feature selection | 15 |
care system | 15 |
findings suggest | 15 |
greenhouse gas | 15 |
ncov spike | 15 |
epidemiological studies | 15 |
enzymatic activities | 15 |
mediated mrna | 15 |
real time | 15 |
coronavirus open | 15 |
linear regression | 15 |
unknown etiology | 15 |
pacientes hospitalizados | 15 |
por coronavirus | 15 |
detect sars | 15 |
del personal | 15 |
studies showed | 15 |
los recursos | 15 |
coronavirus main | 15 |
animal model | 15 |
murine hepatitis | 15 |
lung cancer | 15 |
respiratory pathogens | 15 |
corticosteroid treatment | 15 |
spike gene | 15 |
south africa | 15 |
storm syndromes | 15 |
obstructive pulmonary | 15 |
coronavirus diseases | 15 |
final manuscript | 15 |
molecular evolution | 15 |
bronchial epithelial | 15 |
old drug | 15 |
nuevo coronavirus | 15 |
vitro antiviral | 15 |
coronavirus may | 15 |
favor fundamento | 15 |
surface glycoprotein | 14 |
cellular entry | 14 |
like symptoms | 14 |
policing social | 14 |
dans le | 14 |
treating sars | 14 |
hiv protease | 14 |
nosocomial transmission | 14 |
care medicine | 14 |
first step | 14 |
membrane oxygenation | 14 |
microbiology reviews | 14 |
statistical analysis | 14 |
mediated immune | 14 |
zero lockdown | 14 |
severely affected | 14 |
kcal mol | 14 |
pharmaceutical interventions | 14 |
recovery rate | 14 |
accessory protein | 14 |
pcr test | 14 |
chinese authorities | 14 |
first two | 14 |
asociado con | 14 |
first covid | 14 |
lesser extent | 14 |
higher mortality | 14 |
pandemic will | 14 |
para evaluar | 14 |
coronavirus isolates | 14 |
female candidates | 14 |
transcription factor | 14 |
taken together | 14 |
older age | 14 |
chinese herbal | 14 |
recombinant adenovirus | 14 |
like disease | 14 |
containment measures | 14 |
pathogenic human | 14 |
novel mammalian | 14 |
proteins involved | 14 |
cells via | 14 |
mild respiratory | 14 |
cardiovascular complications | 14 |
positive rate | 14 |
growth factor | 14 |
clinical benefit | 14 |
remains unknown | 14 |
combination lopinavir | 14 |
abnormal coagulation | 14 |
en paciente | 14 |
ct scans | 14 |
es necesario | 14 |
possible cause | 14 |
viral fusion | 14 |
largest number | 14 |
neutralizing monoclonal | 14 |
associated sars | 14 |
apparent efficacy | 14 |
global economy | 14 |
species severe | 14 |
cord blood | 14 |
viral antigens | 14 |
test kits | 14 |
genomic sequences | 14 |
mers outbreak | 14 |
negative results | 14 |
media briefing | 14 |
ha demostrado | 14 |
results showed | 14 |
five cases | 14 |
highly conserved | 14 |
con pacientes | 14 |
current scenario | 14 |
previous research | 14 |
deben ser | 14 |
virus vaccines | 14 |
princess cruise | 14 |
induced lung | 14 |
acute myocardial | 14 |
probable sars | 14 |
comparative therapeutic | 14 |
financial support | 14 |
shown apparent | 14 |
kynurenine ratio | 14 |
understanding sars | 14 |
adult cattle | 14 |
fusion protein | 14 |
combination therapy | 14 |
identify potential | 14 |
president trump | 14 |
also observed | 14 |
fecal samples | 14 |
rhesus macaque | 14 |
arginine kynurenine | 14 |
cov shedding | 14 |
conformational changes | 14 |
acid sequence | 14 |
lymphocyte counts | 14 |
angiotensinconverting enzyme | 14 |
still unknown | 14 |
complement activation | 14 |
alto riesgo | 14 |
virus isolated | 14 |
lymphocyte subsets | 14 |
zoonotic coronaviruses | 14 |
coronavirus fusion | 14 |
case definition | 14 |
late december | 14 |
therapeutic potential | 14 |
operating room | 14 |
clinical samples | 14 |
first known | 14 |
emergency physicians | 14 |
las primeras | 14 |
resisting trump | 14 |
donde se | 14 |
lung tissue | 14 |
two cases | 14 |
moral self | 14 |
genes encoding | 14 |
human neutralizing | 14 |
el traslado | 14 |
countries around | 14 |
vital role | 14 |
cov detection | 14 |
natural killer | 14 |
intrauterine vertical | 14 |
south china | 14 |
del sistema | 14 |
study using | 14 |
las muestras | 13 |
spike receptor | 13 |
patients clinical | 13 |
convalescent sera | 13 |
los criterios | 13 |
controlled clinical | 13 |
disease clinical | 13 |
host response | 13 |
tract infection | 13 |
every day | 13 |
olfactory epithelium | 13 |
accepted article | 13 |
first confirmed | 13 |
interspecies transmission | 13 |
president donald | 13 |
coronavirus research | 13 |
nipah virus | 13 |
chronic hepatitis | 13 |
different parts | 13 |
coronavirus mouse | 13 |
disease course | 13 |
electronic pubication | 13 |
neurologic manifestations | 13 |
viral protein | 13 |
four structural | 13 |
sars pneumonia | 13 |
individual differences | 13 |
following sars | 13 |
epithelial cell | 13 |
develop severe | 13 |
para sars | 13 |
enfermedad por | 13 |
recognition receptors | 13 |
magnetic resonance | 13 |
acute diarrhea | 13 |
endotracheal intubation | 13 |
human health | 13 |
fatality ratio | 13 |
con respecto | 13 |
se le | 13 |
border restrictions | 13 |
personality traits | 13 |
laboratory tests | 13 |
chinese horseshoe | 13 |
economic impact | 13 |
reported deaths | 13 |
seven novel | 13 |
identified coronavirus | 13 |
palm civet | 13 |
reservoir host | 13 |
malayan pangolins | 13 |
retrospective review | 13 |
conjunctival secretions | 13 |
ncov outbreak | 13 |
syndrome virus | 13 |
dendritic cell | 13 |
falla renal | 13 |
basado en | 13 |
large amount | 13 |
motivational postures | 13 |
tener en | 13 |
antiviral compounds | 13 |
national institute | 13 |
among humans | 13 |
two decades | 13 |
age group | 13 |
respiratory viral | 13 |
supports bat | 13 |
body temperature | 13 |
ncov transmission | 13 |
hr domain | 13 |
tested negative | 13 |
health sector | 13 |
death rate | 13 |
genetic characterization | 13 |
un mayor | 13 |
public trust | 13 |
near future | 13 |
hospitalizados con | 13 |
bovine coronaviruses | 13 |
analysis showed | 13 |
patients presenting | 13 |
odds ratio | 13 |
reticulovesicular network | 13 |
con hipoxemia | 13 |
sars cases | 13 |
air travel | 13 |
el objetivo | 13 |
china novel | 13 |
ocular surface | 13 |
high prevalence | 13 |
therapeutic targets | 13 |
registered trials | 13 |
potential intermediate | 13 |
new deaths | 13 |
un protocolo | 13 |
support vector | 13 |
inhibiting sars | 13 |
extracorporeal membrane | 13 |
higher viral | 13 |
plasma exchange | 13 |
estancia en | 13 |
age groups | 13 |
drug interactions | 13 |
passive immunotherapy | 13 |
cell cycle | 13 |
cuenta con | 13 |
pubication ahead | 13 |
throat swab | 13 |
emerging pathogen | 13 |
might also | 13 |
key role | 13 |
disminuir el | 13 |
disease covid | 13 |
million cases | 13 |
three years | 13 |
viral infectivity | 13 |
animal reservoirs | 13 |
european union | 13 |
arabia middle | 13 |
acute phase | 13 |
different animal | 13 |
much higher | 13 |
rna recombination | 13 |
phase ii | 13 |
genome contains | 13 |
cysteine protease | 13 |
protein gene | 13 |
host interactions | 13 |
potential target | 13 |
acquired pneumonia | 13 |
nasal swabs | 13 |
promising results | 13 |
therapeutic option | 13 |
animal health | 13 |
transcription loop | 13 |
coronavirus safety | 13 |
nuclear factor | 13 |
hydrophobic domains | 13 |
last years | 13 |
current evidence | 13 |
serological evidence | 13 |
wuhan coronavirus | 13 |
deltacoronavirus supports | 13 |
ct images | 13 |
samples collected | 13 |
generation sequencing | 13 |
therapeutic development | 13 |
el consentimiento | 13 |
also increased | 13 |
genus deltacoronavirus | 13 |
co emissions | 13 |
open access | 13 |
reduced mortality | 13 |
mayor riesgo | 13 |
sectional study | 13 |
grupo control | 12 |
en salud | 12 |
two major | 12 |
molecular interactions | 12 |
first isolated | 12 |
different strains | 12 |
abo blood | 12 |
le sars | 12 |
poor outcomes | 12 |
recomienda el | 12 |
antiviral agent | 12 |
cyber security | 12 |
eye protection | 12 |
united nations | 12 |
viral structural | 12 |
international concern | 12 |
similar findings | 12 |
asian countries | 12 |
immune function | 12 |
zoonotic diseases | 12 |
detection method | 12 |
infectious virus | 12 |
ng ml | 12 |
potential antiviral | 12 |
cellular immunity | 12 |
times higher | 12 |
severe infection | 12 |
lymph nodes | 12 |
citation network | 12 |
coronavirus type | 12 |
medical records | 12 |
diagnostic test | 12 |
cov replicative | 12 |
wet markets | 12 |
este estudio | 12 |
diseases caused | 12 |
viral pathogens | 12 |
glass opacity | 12 |
syndrome associated | 12 |
pcr assays | 12 |
potential anti | 12 |
nonhuman primates | 12 |
environmental factors | 12 |
clinical evidence | 12 |
newly discovered | 12 |
interaction partners | 12 |
viral vector | 12 |
posted april | 12 |
healthcare facilities | 12 |
emergency response | 12 |
disease prevention | 12 |
might help | 12 |
three different | 12 |
drug development | 12 |
new zealand | 12 |
nucleocapsid proteins | 12 |
seasonal influenza | 12 |
will lead | 12 |
chadox ncov | 12 |
amniotic fluid | 12 |
clinical guide | 12 |
healthcare personnel | 12 |
bacterial infections | 12 |
infectious agent | 12 |
alveolar macrophages | 12 |
sars pathogenesis | 12 |
highest number | 12 |
including covid | 12 |
test positive | 12 |
unclear whether | 12 |
tracto respiratorio | 12 |
cov genomes | 12 |
infectious agents | 12 |
dental care | 12 |
un paciente | 12 |
noneffusive disease | 12 |
long term | 12 |
tertiary care | 12 |
often used | 12 |
future pandemics | 12 |
supply chains | 12 |
transcription polymerase | 12 |
frecuencia respiratoria | 12 |
infections among | 12 |
per million | 12 |
limited data | 12 |
nucleotide sequence | 12 |
insufficient evidence | 12 |
length genome | 12 |
nine pregnant | 12 |
also infect | 12 |
nasopharyngeal samples | 12 |
human trial | 12 |
specific cd | 12 |
emerging pathogens | 12 |
current outbreak | 12 |
illness onset | 12 |
faecal samples | 12 |
term memory | 12 |
median time | 12 |
los resultados | 12 |
rna genomes | 12 |
tissue damage | 12 |
also present | 12 |
serological investigation | 12 |
deceased patients | 12 |
inactivated virus | 12 |
el contexto | 12 |
virus vaccine | 12 |
pacientes recibieron | 12 |
east asian | 12 |
supplementary file | 12 |
clinical data | 12 |
distancing rules | 12 |
cov cl | 12 |
among children | 12 |
time period | 12 |
el rendimiento | 12 |
scoping review | 12 |
virtual screening | 12 |
also showed | 12 |
prone positioning | 12 |
another coronavirus | 12 |
mice infected | 12 |
driven analysis | 12 |
time pcr | 12 |
drug treatment | 12 |
stimulating factor | 12 |
commercially available | 12 |
tests positive | 12 |
nationwide analysis | 12 |
patient care | 12 |
smart cities | 12 |
income countries | 12 |
virus isolation | 12 |
lymphocyte count | 12 |
economic losses | 12 |
protein expression | 12 |
serum antibodies | 12 |
lupus erythematosus | 12 |
coronavirus helicase | 12 |
developing severe | 12 |
new disease | 12 |
cellular membranes | 12 |
nucleoside analogues | 12 |
uso del | 12 |
electron microscope | 12 |
surviving sepsis | 12 |
class ii | 12 |
therapeutic strategy | 12 |
cov antibodies | 12 |
transcription complex | 12 |
ces virus | 12 |
sequence homology | 12 |
studies suggest | 12 |
treatment strategies | 12 |
diarrhoea syndrome | 12 |
ace inhibitors | 12 |
significantly reduced | 12 |
i interferons | 12 |
enveloped viruses | 12 |
virus type | 12 |
states clinical | 12 |
evolutionary perspective | 12 |
viral pathogenesis | 12 |
genome composition | 12 |
stool samples | 12 |
health response | 12 |
puede emitir | 12 |
suspected case | 12 |
leader sequence | 12 |
novel covs | 12 |
antiviral activities | 12 |
nan doi | 12 |
epidemiologic features | 12 |
coronavirus assembly | 12 |
increased levels | 12 |
potential drug | 12 |
isolation room | 12 |
retrospective case | 12 |
se encuentra | 12 |
modified endoplasmic | 12 |
immune activation | 12 |
viruses including | 12 |
ongoing covid | 12 |
acute diarrhoea | 12 |
clinical efficacy | 12 |
china reported | 12 |
supplementary table | 12 |
parainfluenza virus | 12 |
therapeutic target | 12 |
interferon antagonists | 12 |
future studies | 12 |
expert consensus | 12 |
human angiotensin | 12 |
transmission rate | 12 |
short time | 12 |
heme oxygenase | 12 |
potential targets | 12 |
renal aguda | 12 |
infected mice | 12 |
worth noting | 12 |
ground glass | 11 |
golgi complex | 11 |
clinical manifestation | 11 |
novel viruses | 11 |
unknown origin | 11 |
retrospective analysis | 11 |
network analysis | 11 |
possible role | 11 |
south america | 11 |
relatively low | 11 |
high expression | 11 |
virus outbreak | 11 |
cov nucleocapsid | 11 |
related covs | 11 |
patients suffering | 11 |
masked palm | 11 |
inflammatory mediators | 11 |
recent reports | 11 |
por un | 11 |
human host | 11 |
tract disease | 11 |
hydrogen bonds | 11 |
fusion inhibitor | 11 |
respiratorio agudo | 11 |
north american | 11 |
mitigation strategies | 11 |
el fin | 11 |
ct features | 11 |
current situation | 11 |
tissue culture | 11 |
medical care | 11 |
among close | 11 |
hiv infection | 11 |
trump movement | 11 |
higher compared | 11 |
human infections | 11 |
severe pulmonary | 11 |
international spread | 11 |
el punto | 11 |
los hallazgos | 11 |
reports suggest | 11 |
different levels | 11 |
cuidados paliativos | 11 |
existe una | 11 |
nsp proteins | 11 |
antibodies may | 11 |
islands model | 11 |
el virus | 11 |
multicentre trial | 11 |
bat covs | 11 |
large uncertainties | 11 |
specific antiviral | 11 |
coronavirus spread | 11 |
con tcz | 11 |
plastic surgery | 11 |
dental practice | 11 |
body fluids | 11 |
large scale | 11 |
cl protease | 11 |
virus detection | 11 |
disgust propensity | 11 |
recombination events | 11 |
un grupo | 11 |
antibody detection | 11 |
ill adults | 11 |
coronavirus outbreaks | 11 |
sepsis campaign | 11 |
saliva samples | 11 |
sample collection | 11 |
total confirmed | 11 |
higher levels | 11 |
human diseases | 11 |
small sample | 11 |
des coronavirus | 11 |
trump coronavirus | 11 |
health anxiety | 11 |
recent report | 11 |
primary infection | 11 |
molecular weight | 11 |
convalescent patients | 11 |
virological assessment | 11 |
estudio retrospectivo | 11 |
del plasma | 11 |
severely ill | 11 |
posterior oropharyngeal | 11 |
sequence comparison | 11 |
curve fitting | 11 |
order nidovirales | 11 |
experimental infection | 11 |
kidney disease | 11 |
new human | 11 |
viral dynamics | 11 |
innate antiviral | 11 |
viral outbreaks | 11 |
different coronaviruses | 11 |
zoonotic potential | 11 |
como un | 11 |
cov vaccine | 11 |
como los | 11 |
contaminated surfaces | 11 |
recently published | 11 |
confidence interval | 11 |
median age | 11 |
emerging sars | 11 |
less toxic | 11 |
pulmonary pathology | 11 |
infectious respiratory | 11 |
breast milk | 11 |
deaths reported | 11 |
ser una | 11 |
membrane rearrangements | 11 |
plus interferon | 11 |
del tracto | 11 |
vaccine induces | 11 |
increased mortality | 11 |
human macrophages | 11 |
data regarding | 11 |
con mayor | 11 |
del equipo | 11 |
los respiradores | 11 |
time course | 11 |
may prove | 11 |
coronaviruses sars | 11 |
en wuhan | 11 |
publicly available | 11 |
pattern recognition | 11 |
cases may | 11 |
subcellular localization | 11 |
secretory pathway | 11 |
less severe | 11 |
igg antibody | 11 |
much lower | 11 |
pcr results | 11 |
lymphocyte ratio | 11 |
autophagy induction | 11 |
pandemic virus | 11 |
subgenomic mrnas | 11 |
critical patients | 11 |
pneumonia caused | 11 |
throat swabs | 11 |
environmental conditions | 11 |
trial clinical | 11 |
current stress | 11 |
aumento en | 11 |
enfermedad severa | 11 |
surgical mask | 11 |
icu days | 11 |
may explain | 11 |
thrombotic complications | 11 |
distributive fairness | 11 |
risk assessments | 11 |
virus particle | 11 |
statistically significant | 11 |
fatal cases | 11 |
organ cultures | 11 |
todas las | 11 |
inactivated sars | 11 |
systemic lupus | 11 |
cp therapy | 11 |
th day | 11 |
include fever | 11 |
efectos adversos | 11 |
thrusting coronaviruses | 11 |
laboratory diagnosis | 11 |
molecular diagnosis | 11 |
el primer | 11 |
african countries | 11 |
will require | 11 |
coronaviruses coronavirus | 11 |
macrophage activation | 11 |
cerebrovascular disease | 11 |
suspected patients | 11 |
transmission route | 11 |
many patients | 11 |
recombination event | 11 |
healthy controls | 11 |
infections caused | 11 |
proteolytic processing | 11 |
ifn response | 11 |
confirmed sars | 11 |
neonates born | 11 |
los siguientes | 11 |
terminal region | 11 |
pacientes tratados | 11 |
proximal origin | 11 |
new england | 11 |
toxic derivative | 11 |
clinical application | 11 |
proteolytic cleavage | 11 |
preliminary study | 11 |
like covid | 11 |
los medicamentos | 11 |
protein induces | 11 |
macrophage responses | 11 |
commonly used | 11 |
antiviral innate | 11 |
coronavirus using | 11 |
early humoral | 11 |
cd cd | 11 |
species barriers | 11 |
lung ultrasound | 11 |
vitro activity | 11 |
blood group | 11 |
respiratoria aguda | 11 |
clinical analysis | 11 |
medical research | 11 |
mediated inflammatory | 11 |
umbilical cord | 11 |
lipid bilayer | 11 |
blood mononuclear | 11 |
replicase gene | 11 |
first week | 11 |
also important | 11 |
angiotensin i | 11 |
avian species | 11 |
research areas | 11 |
el nivel | 11 |
case studies | 11 |
cell transplantation | 10 |
respiratory coronaviruses | 10 |
en estos | 10 |
tourism paradigm | 10 |
cov case | 10 |
leukemia virus | 10 |
hospitalized adults | 10 |
symptomatic cases | 10 |
eventos adversos | 10 |
pneumonia patients | 10 |
coronavirus regulations | 10 |
pcr para | 10 |
oropharyngeal saliva | 10 |
years ago | 10 |
transplant recipient | 10 |
global spread | 10 |
european society | 10 |
coronavirus fear | 10 |
data available | 10 |
high blood | 10 |
learning models | 10 |
symptoms include | 10 |
wide variety | 10 |
national institutes | 10 |
pharmaceutical companies | 10 |
traced back | 10 |
realizar el | 10 |
highly potent | 10 |
per population | 10 |
cov strains | 10 |
disease associated | 10 |
en esta | 10 |
von sars | 10 |
daily basis | 10 |
se pueden | 10 |
double membrane | 10 |
calf diarrhoea | 10 |
weight loss | 10 |
infected cats | 10 |
high level | 10 |
vaccinia virus | 10 |
porcine hemagglutinating | 10 |
healthcare systems | 10 |
intermediate compartment | 10 |
symptoms may | 10 |
days later | 10 |
des hcov | 10 |
newly synthesized | 10 |
human cov | 10 |
coronavirus human | 10 |
nasopharyngeal swabs | 10 |
protective role | 10 |
cause respiratory | 10 |
radiological findings | 10 |
found throughout | 10 |
decision tree | 10 |
wild animal | 10 |
measures taken | 10 |
acid amplification | 10 |
pulmonary inflammation | 10 |
first coronavirus | 10 |
canine infectious | 10 |
care professionals | 10 |
blocking sars | 10 |
diarrhea syndrome | 10 |
interstitial pneumonia | 10 |
study involving | 10 |
attenuated virus | 10 |
human body | 10 |
severe lung | 10 |
close proximity | 10 |
coronavirus strain | 10 |
gene encoding | 10 |
care providers | 10 |
high throughput | 10 |
fusion peptide | 10 |
ill icu | 10 |
evitar el | 10 |
mg day | 10 |
zoonotic viruses | 10 |
potent binding | 10 |
related viruses | 10 |
hand washing | 10 |
data sharing | 10 |
causing sars | 10 |
structural analysis | 10 |
serological study | 10 |
treated patients | 10 |
viral agents | 10 |
tomar decisiones | 10 |
cell infection | 10 |
using rt | 10 |
hipoxemia refractaria | 10 |
potent antiviral | 10 |
antibody titer | 10 |
icu beds | 10 |
optimized dosing | 10 |
pregnancy outcomes | 10 |
high rate | 10 |
interferon alfacon | 10 |
membrane proteins | 10 |
four cases | 10 |
el procedimiento | 10 |
salud mental | 10 |
cells expressing | 10 |
inflammatory drugs | 10 |
prothrombin time | 10 |
coronavirus era | 10 |
inhibitory activity | 10 |
diagnostic tests | 10 |
relacionadas con | 10 |
creatinine arginine | 10 |
acid sequences | 10 |
golgi intermediate | 10 |
blood cells | 10 |
may serve | 10 |
todo el | 10 |
health officials | 10 |
patients reported | 10 |
molecular mechanism | 10 |
transplant patients | 10 |
also include | 10 |
also considered | 10 |
known coronaviruses | 10 |
mitigation measures | 10 |
coronavirus genomic | 10 |
also help | 10 |
debe considerar | 10 |
pressure ventilation | 10 |
du sars | 10 |
infection rates | 10 |
single center | 10 |
personal data | 10 |
reverse genetics | 10 |
pip disease | 10 |
nsp complex | 10 |
existe evidencia | 10 |
syndrome isolation | 10 |
water resources | 10 |
una mayor | 10 |
fundamental motive | 10 |
rapidly spread | 10 |
map diagrams | 10 |
protease activity | 10 |
cytokines like | 10 |
based detection | 10 |
coronavirus middle | 10 |
evolutionary tourism | 10 |
fusion core | 10 |
i will | 10 |
single stranded | 10 |
antiviral remdesivir | 10 |
evolutionary analysis | 10 |
en algunos | 10 |
cited publication | 10 |
moderate coronavirus | 10 |
icu care | 10 |
viral replicase | 10 |
water consumption | 10 |
natural infection | 10 |
shed light | 10 |
mrna vaccines | 10 |
protein synthesis | 10 |
recomienda utilizar | 10 |
similar symptoms | 10 |
mild upper | 10 |
preventive measure | 10 |
adverse outcomes | 10 |
functional assessment | 10 |
testing positive | 10 |
known protein | 10 |
molecular basis | 10 |
por los | 10 |
host proteins | 10 |
specific treatment | 10 |
sputum production | 10 |
porcine transmissible | 10 |
ex vivo | 10 |
adenovirus vector | 10 |
symptomatic patient | 10 |
group ii | 10 |
sequence alignment | 10 |
old man | 10 |
plasma transfusion | 10 |
may well | 10 |
develop vaccines | 10 |
two studies | 10 |
lung lesions | 10 |
wild carnivores | 10 |
ang ii | 10 |
las horas | 10 |
randomised controlled | 10 |
remain asymptomatic | 10 |
syndrome caused | 10 |
coronavirus molecular | 10 |
wuhan clinical | 10 |
adjunctive therapy | 10 |
en tiempos | 10 |
pressure isolation | 10 |
critical role | 10 |
new drugs | 10 |
effective vaccines | 10 |
early outbreak | 10 |
scientific publications | 10 |
risk analysis | 10 |
inactivated vaccine | 10 |
recomienda considerar | 10 |
inflammatory monocytes | 10 |
swab samples | 10 |
health approach | 10 |
treat coronavirus | 10 |
transmembrane protease | 10 |
neutralizing epitopes | 10 |
extracellular traps | 10 |
social dominance | 10 |
secondary bacterial | 10 |
preterm delivery | 10 |
canine respiratory | 10 |
rhesus monkeys | 10 |
functional exhaustion | 10 |
previous day | 10 |
data sets | 10 |
virus binding | 10 |
nasal cavity | 10 |
direct viral | 10 |
epidemic diarrhoea | 10 |
current understanding | 10 |
several countries | 10 |
first identified | 10 |
approved antiviral | 10 |
living cells | 10 |
relative humidity | 10 |
del inicio | 10 |
highly sensitive | 10 |
subunit vaccines | 10 |
natural reservoir | 10 |
environmental impacts | 10 |
mediated viral | 10 |
type pneumocytes | 10 |
cov virus | 10 |
first detection | 10 |
stranded positive | 10 |
potential drugs | 10 |
infection diagnosis | 10 |
cultured cells | 10 |
disease negative | 10 |
naturally occurring | 10 |
los epp | 10 |
host interactome | 10 |
high degree | 10 |
named sars | 10 |
physical contact | 10 |
beluga whale | 10 |
international health | 10 |
immune cell | 10 |
research team | 10 |
vast majority | 10 |
requiring hospitalization | 10 |
control group | 10 |
carbon emissions | 10 |
two large | 10 |
bioinformatics analysis | 10 |
transmembrane protein | 10 |
small number | 10 |
dosing design | 10 |
rational use | 10 |
potential risk | 10 |
cardiovascular diseases | 10 |
coronavirus transmission | 10 |
organ damage | 10 |
estancia hospitalaria | 10 |
domain complexed | 10 |
elective surgery | 10 |
coronavirus causing | 10 |
angiotensin receptor | 10 |
combined antibody | 10 |
puede considerar | 10 |
competing interests | 10 |
contra el | 10 |
starting point | 10 |
se encuentran | 10 |
commons attribution | 10 |
high specificity | 10 |
influenza infection | 10 |
england journal | 10 |
well known | 10 |
decision trees | 9 |
interferon alfa | 9 |
temporal profiles | 9 |
data science | 9 |
notch signaling | 9 |
wholesale market | 9 |
high fever | 9 |
diagnostic testing | 9 |
doubling time | 9 |
functional analysis | 9 |
ic del | 9 |
published studies | 9 |
well established | 9 |
scientific literature | 9 |
cov transmission | 9 |
standard treatment | 9 |
antiviral compound | 9 |
sars vaccine | 9 |
three cases | 9 |
single day | 9 |
del compromiso | 9 |
testing capacity | 9 |
infected animals | 9 |
common clinical | 9 |
independent variables | 9 |
experimental studies | 9 |
per se | 9 |
pathogen severe | 9 |
polymerase activity | 9 |
outcome measurement | 9 |
therapeutic approach | 9 |
binding sites | 9 |
disease may | 9 |
renal failure | 9 |
el proceso | 9 |
potent neutralizing | 9 |
older adults | 9 |
interim clinical | 9 |
se considera | 9 |
dentro del | 9 |
air traffic | 9 |
low levels | 9 |
one example | 9 |
herbal medicines | 9 |
cell proliferation | 9 |
adverse reactions | 9 |
different time | 9 |
coronavirus neutralising | 9 |
may become | 9 |
protective immune | 9 |
china seafood | 9 |
ncov acute | 9 |
second wave | 9 |
coronavirus hemagglutinin | 9 |
room temperature | 9 |
viral polymerase | 9 |
china covid | 9 |
water buffalo | 9 |
nonhuman primate | 9 |
evolutionary history | 9 |
subgenus embecovirus | 9 |
may still | 9 |
cesarean section | 9 |
des infections | 9 |
seafood wholesale | 9 |
del sars | 9 |
since january | 9 |
young children | 9 |
con sars | 9 |
critical review | 9 |
will likely | 9 |
communion cup | 9 |
acetylated sialic | 9 |
binding energy | 9 |
hospitalized covid | 9 |
evaluar el | 9 |
protein contains | 9 |
newborn infants | 9 |
viral attachment | 9 |
endosomal ph | 9 |
viral spread | 9 |
infection covid | 9 |
nucleoside analogue | 9 |
health agencies | 9 |
known human | 9 |
janus kinase | 9 |
growth model | 9 |
per year | 9 |
aged years | 9 |
lung inflammation | 9 |
clinical treatment | 9 |
para establecer | 9 |
se deben | 9 |
transmembrane domains | 9 |
triple combination | 9 |
initial stages | 9 |
phase clinical | 9 |
poverty incidence | 9 |
para determinar | 9 |
cov strain | 9 |
haemolytic anaemia | 9 |
chest radiographic | 9 |
vero cells | 9 |
ecosystem services | 9 |
working group | 9 |
newly emerged | 9 |
large extent | 9 |
transcription complexes | 9 |
pulmonary hypertension | 9 |
risk perception | 9 |
blood vessels | 9 |
patients covid | 9 |
individual countries | 9 |
cov rbd | 9 |
based methods | 9 |
two groups | 9 |
enteric coronaviruses | 9 |
virus sars | 9 |
early infection | 9 |
pour les | 9 |
ill patient | 9 |
zoonotic origin | 9 |
variant sites | 9 |
infection caused | 9 |
prevention measures | 9 |
coronavirus severe | 9 |
directly related | 9 |
clinical evaluation | 9 |
advanced age | 9 |
personal sanitario | 9 |
protective gears | 9 |
caused severe | 9 |
may include | 9 |
new evidence | 9 |
viral membrane | 9 |
soporte ventilatorio | 9 |
spread across | 9 |
limited number | 9 |
highly effective | 9 |
social isolation | 9 |
mild illness | 9 |
children hospitalized | 9 |
acid residues | 9 |
economic impacts | 9 |
mechanically ventilated | 9 |
mg twice | 9 |
highly specific | 9 |
approved compound | 9 |
primers lpw | 9 |
viral strains | 9 |
diagnose novel | 9 |
appropriate ppe | 9 |
previously known | 9 |
pacientes adultos | 9 |
expressing cells | 9 |
beneficial effects | 9 |
review article | 9 |
study protocol | 9 |
del estudio | 9 |
block sars | 9 |
drug candidates | 9 |
day mortality | 9 |
fruit bats | 9 |
airborne transmission | 9 |
solved protein | 9 |
clinical suspicion | 9 |
current research | 9 |
trial hydroxychloroquine | 9 |
index case | 9 |
replication transcription | 9 |
stimulated gene | 9 |
major outbreak | 9 |
center experience | 9 |
organizing pneumonia | 9 |
past days | 9 |
people worldwide | 9 |
potential covid | 9 |
th march | 9 |
may act | 9 |
silico studies | 9 |
compound library | 9 |
false negative | 9 |
por encima | 9 |
two patients | 9 |
infections respiratoires | 9 |
venous thrombosis | 9 |
multiple shedding | 9 |
molecular patterns | 9 |
pharmacologic treatments | 9 |
another potential | 9 |
tract specimens | 9 |
th may | 9 |
protective effect | 9 |
economic recovery | 9 |